SIGA Technologies, Inc. (SIGA)

NASDAQ: SIGA · IEX Real-Time Price · USD
6.67
-0.88 (-11.66%)
At close: Jun 14, 2024, 4:00 PM
6.80
+0.13 (1.95%)
After-hours: Jun 14, 2024, 7:52 PM EDT
-11.66%
Market Cap 474.39M
Revenue (ttm) 157.02M
Net Income (ttm) 79.26M
Shares Out 71.12M
EPS (ttm) 1.10
PE Ratio 6.06
Forward PE 7.47
Dividend n/a
Ex-Dividend Date n/a
Volume 1,138,008
Open 7.65
Previous Close 7.55
Day's Range 6.49 - 7.65
52-Week Range 4.22 - 10.83
Beta 0.94
Analysts n/a
Price Target n/a
Earnings Date Aug 6, 2024

About SIGA

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. [Read more]

Sector Healthcare
IPO Date Sep 9, 1997
Employees 45
Stock Exchange NASDAQ
Ticker Symbol SIGA
Full Company Profile

Financial Performance

In 2023, SIGA's revenue was $139.92 million, an increase of 26.31% compared to the previous year's $110.78 million. Earnings were $68.07 million, an increase of 100.76%.

Financial Statements

News

SIGA Reports Financial Results for Three Months Ended March 31, 2024

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 3...

5 weeks ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference ...

6 weeks ago - GlobeNewsWire

SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that i...

2 months ago - GlobeNewsWire

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call ...

3 months ago - GlobeNewsWire

SIGA Declares Special Cash Dividend of $0.60 Per Share

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special ca...

3 months ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conferenc...

3 months ago - GlobeNewsWire

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Ng...

5 months ago - GlobeNewsWire

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® -

7 months ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...

8 months ago - GlobeNewsWire

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the creation...

8 months ago - GlobeNewsWire

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Ja...

10 months ago - GlobeNewsWire

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023

- In July, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® -

11 months ago - GlobeNewsWire

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current Contract reflects continuing global action to enhance smallpox pre...

11 months ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...

11 months ago - GlobeNewsWire

SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

Inaugural meeting on June 28-30, 2023, to include updates from leading experts on strategies to plan for and address broad range of potential global health risks including biological and viral disease...

1 year ago - GlobeNewsWire

SIGA Reports Financial Results for Three Months Ended March 31, 2023

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 3...

1 year ago - GlobeNewsWire

SIGA Declares Special Cash Dividend of $0.45 Per Share

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special cash...

1 year ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conferenc...

1 year ago - GlobeNewsWire

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022

- Approximately $71 Million of International Product Sales in 2022 -

1 year ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results

NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...

1 year ago - GlobeNewsWire

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023

SIGA Board of Directors has initiated search for new CEO; Dr. Gomez expected to remain in position as CEO until the search is completed to support the transition to a new CEO in 2023 SIGA Board of Dir...

1 year ago - GlobeNewsWire

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022

- Approximately $61 Million of International Sales in the Third Quarter –

1 year ago - GlobeNewsWire

SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...

1 year ago - GlobeNewsWire

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on ...

1 year ago - GlobeNewsWire

SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®

- In 2022, the U.S. Department of Defense has Awarded Procurement Contracts for the Purchase of up to $18.1 Million of Oral TPOXX – - In 2022, the U.S. Department of Defense has Awarded Procurement Co...

1 year ago - GlobeNewsWire